Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411

Bibliography

• Sterne JA, Hernan MA, Ledergerber B, Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378-84
   PubMed Web of Science ®Google Scholar
• Lubinski C, Aberg J, Bardeguez AD, HIV policy: the path forward – a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009;20:1335-44
   Web of Science ®Google Scholar
• Kaufmann GR, Perrin L, Pantaleo G, CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003;163:2187-95
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E, T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534-43
   PubMed Web of Science ®Google Scholar
• Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 2003;5:172-7
   PubMedGoogle Scholar
• Brenchley JM, Price DA, Schacker TW, Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-71
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-16
   PubMed Web of Science ®Google Scholar
• Foli A, Maiocchi MA, Lisziewicz J, Lori F. A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. J Infect Dis 2007;196:1409-15
   PubMed Web of Science ®Google Scholar
• Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991;12:102-5
   PubMedGoogle Scholar
• Meyaard L, Otto SA, Jonker RR, Programmed death of T cells in HIV-1 infection. Science 1992;257:217-19
   PubMed Web of Science ®Google Scholar
• Finkel TH, Tudor-Williams G, Banda NK, Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995;1:129-34
   PubMed Web of Science ®Google Scholar
• Grossman Z, Paul WE. The impact of HIV on naïve T-cell homeostasis. Nat Med 2000;6:976-7
   PubMed Web of Science ®Google Scholar
• McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001;410:974-9
   PubMed Web of Science ®Google Scholar
• Hellerstein MK, Hoh RA, Hanley MB, Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest 2003;112:956-66
   PubMed Web of Science ®Google Scholar
• Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172
   PubMed Web of Science ®Google Scholar
• De Forni D, Stevens MR, Lori F. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model HIV/AIDS. Br J Pharmacol 2010;161:830-43
   PubMed Web of Science ®Google Scholar
• Murray SM, Down CM, Boulware DR, Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84:12082-6
   PubMed Web of Science ®Google Scholar
• Read SW, DeGrezia M, Ciccone EJ, The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PloS One 2010;5:e11937
   PubMed Web of Science ®Google Scholar
• Montoya CJ, Jaimes F, Higuita EA, Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 2009;10:41
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22
   PubMed Web of Science ®Google Scholar
• Navarra P, Preziosi P. Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 1999;29:249-55
   PubMed Web of Science ®Google Scholar
• Smith CH. Use of hydroxyurea in psoriasis. Clin Exp Dermatol 1999;24:2-6
   PubMed Web of Science ®Google Scholar
• Davies SC, Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Rev 2003;17:99-109
   PubMed Web of Science ®Google Scholar
• Lori F, Malykh A, Cara A, Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-5
   PubMed Web of Science ®Google Scholar
• Lori F, Gallo RC, Malykh A, Didanosine but not high doses of hydroxyurea rescue pigtail macaque from a lethal dose of SIV(smmpbj14). AIDS Res Hum Retroviruses 1997;13:1083-8
   PubMed Web of Science ®Google Scholar
• Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998;55:1551-6
   PubMed Web of Science ®Google Scholar
• Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1-10
   PubMed Web of Science ®Google Scholar
• Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-21
   PubMed Web of Science ®Google Scholar
• Gao WY, Johns DG, Chokekuchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7
   PubMed Web of Science ®Google Scholar
• De Boer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-70
   PubMed Web of Science ®Google Scholar
• Ravot E, Lisziewicz J, Lori F. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide. Drugs 1999;58:953-63
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Saf 2003;26:605-24
   PubMed Web of Science ®Google Scholar
• Kelly LM, Lisziewicz J, Lori F. “Virostatics” as a potential new class of HIV drugs. Curr Pharm Des 2004;10:4103-20
   PubMed Web of Science ®Google Scholar
• Heredia A, Davis C, Amoroso A, Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA 2003;100:4179-84
   PubMed Web of Science ®Google Scholar
• Biron F, Lucht F, Peyramond D, Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res 1996;29:111-13
   PubMed Web of Science ®Google Scholar
• Foli A, Lori F, Maserati R, Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Antivir Ther 1997;2:31-8
   PubMedGoogle Scholar
• Vila J, Nugier F, Bargues G, Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997;350:635-6
   PubMed Web of Science ®Google Scholar
• Montaner JS, Zala C, Conway B, A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-6
   PubMed Web of Science ®Google Scholar
• Lori F, Malykh AG, Foli A, Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-9
   PubMed Web of Science ®Google Scholar
• Rutschmann OT, Opravil M, Iten A, A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-7
   PubMed Web of Science ®Google Scholar
• Frank I, Bosch RJ, Fiscus S, Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 2004;20:916-26
   PubMed Web of Science ®Google Scholar
• Lori F, Pollard RB, Whitman L, Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses 2005;21:263-72
   PubMed Web of Science ®Google Scholar
• Lori F, Foli A, Groff A, Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (‘virostatic’) mechanisms. AIDS 2005;19:1173-81
   PubMed Web of Science ®Google Scholar
• Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72
   PubMed Web of Science ®Google Scholar
• Foli A, Benvenuto F, Piccinini G, Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001;15:1687-94
   PubMed Web of Science ®Google Scholar
• Katabira E, Cahn P, Lange J, Both Immune Activation and Viral Load are Reduced Within 28 Days by VS411, the First AntiViral-HyperActivation Limiting Therapeutic (AV-HALT). A Phase II Study. Poster THPE0066 presented at XVIII International AIDS Conference; 18 – 23 July 2010; Vienna, Austria
   Google Scholar
• Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19:11-19
   PubMed Web of Science ®Google Scholar
• Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrol Agents Chemother 1999;43:2046-50
   PubMed Web of Science ®Google Scholar
• Lori F, Foli A, Maserati R, Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clin Trials 2002;3:115-24
   PubMedGoogle Scholar
• Lori F. Virostatics: a new frontier in the treatment of HIV/AIDS. J Acquir Immune Defic Syndr 2006;42:S1-3
   PubMed Web of Science ®Google Scholar
• Miller S. Hydroxyurea: eight years' experience. J Acquir Immune Defic Syndr 2006;42:S16-17
   Google Scholar
• Hunt PW, Brenchley, Sinclair E, Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-33
   PubMed Web of Science ®Google Scholar